Stephanie Baum , 2025-05-05 11:30:00
It can cost tens of millions to develop a medical device and bring it to market. It can take $1 billion or more to develop a drug. Companies that can facilitate the financial components of this process for early stage life science companies can ease the path to market. A discussion about early stage life science investment and how a banking platform approach could be a resource for the needs of entrepreneurs across biotech, diagnostics and other life science companies will be the focus of a webinar sponsored by Mercury, a fintech company that provides a platform for banking services.
Scheduled for May 8 at 1 pm ET, the conversation will include Morgan Cheatham, head of healthcare and life sciences at Breyer Capital, Gurdane Bhutani, founder and managing partner of MBX Capital, and will be moderated by Mercury Head of Healthcare and Life Sciences Ben Kromnick.
Among the talking points are:
- With NIH grant funding cutbacks, what is the opportunity for private institutions to step in?
- How to develop a strategy that assesses the use of angel investors, SBIR grants, and strategic investors
- The trends toward less government investment in research and development coupled with the rise of AI present challenges and opportunities for companies – how are they managing them?
- Mercury’s role in helping companies navigate the financial challenges of a life science startup from the financial workflows essential to any company to enabling them to clearly understand and access the HLS financial markets through its ecosystem and expertise
- How Mercury works with life science incubators and accelerators such as Mass Challenge and Cancer X
To register for the webinar, How can Fintech Make It Easier for Early Stage Life Science Companies to Grow, fill out the form below:
Mercury is a financial technology company, not a bank. Banking services provided by Choice Financial Group, Column N.A., and Evolve Bank & Trust, Members FDIC.
